Abstract
Hypoxia-induced stress plays a central role in retinal vascular disease and cancer. Increased hypoxia-inducible factor-1α (Hif-1α) expression leads to HIF-1 formation and the production of vascular endothelial growth factor (VEGF). Cytokines, including insulin-like growth factor-1 (IGF-1), also stimulate VEGF secretion. In this study, we examined the relationship between IGF-1 signaling, HIF-1α protein turnover and VEGF secretion in the ARPE-19 retinal pigment epithelial cell line. Northern analysis revealed that IGF-1 stimulated Hif-1α message expression, whereas the hypoxia-mimetic CoCl2 did not. CoCl2 treatment increased Hif-1α protein accumulation to a greater extent than IGF-1 treatment. However, IGF-1 stimulated a more significant increase in VEGF secretion. IGF-1-stimulated VEGF promoter activity was phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR (mammalian target of rapamycin)-dependent, whereas VEGF secretion was only partially reduced by inhibition of PI3K/Akt/mTOR and HIF-1 activities. Analysis of VEGF promoter truncation mutants indicated that sensitivity to CoCl2 was hypoxia response element (HRE)-dependent with the region upstream of the HRE conferring IGF-1 sensitivity. In conclusion, IGF-1 regulates VEGF expression and secretion via HIF-1-dependent and -independent pathways.
Footnotes
-
This work was supported, in part, by Grant CA78887 from the National Institutes of Health, a Department of Defense grant to Hollings Cancer Center, (N6311601MD10004) and a research award from the American Health Assistance Foundation to S.A.R. M.G.S. was funded in part, by an Abney Foundation Research Scholars Award. A portion of this work was presented at the Retinal and Choroidal Angiogenesis Scientific Symposium; 2005 Oct 15-16; Nashville, TN.
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.106.104158.
-
ABBREVIATIONS: VEGF, vascular endothelial growth factor; CNV, choroidal neovascularization; RPE, retinal pigment epithelium; IGF, insulin-like growth factor; IGFBP, IGF-binding protein; IGF-1R, IGF-1 receptor; HIF-1, hypoxia-inducible factor-1; HRE, hypoxia response element; PI3, phosphatidylinositol; PI3K, phosphatidylinositol 3-kinase; MAPK, mitogen-activated protein kinase kinase/mitogen-activated protein kinase; LY294002, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; CsA, cyclosporin A; ERK, extracellular signal-regulated kinase; kb, kilobase(s); PBS, phosphate-buffered saline; bp, base pair(s); BCA, bicinchoninic acid; MOPS, 4-morpholinepropanesulfonic acid; mTOR, mammalian target of rapamycin; eIF4E, eukaryotic initiation factor 4E; 4E-BP, eIF4e-binding protein; pVHL, von Hippel-Lindau protein.
-
↵ The online version of this article (available at http://jpet.aspetjournals.org) contains supplemental material.
- Received March 7, 2006.
- Accepted May 4, 2006.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|